Positron emission tomography-computed tomography evaluation for recurrent differentiated thyroid carcinoma

被引:6
作者
Makeieff, M. [1 ]
Burcia, V. [1 ]
Raingeard, I. [2 ]
Eberle, M. C. [3 ]
Cartier, C. [1 ]
Garrel, R. [1 ]
Crampette, L. [1 ]
Guerrier, B. [1 ]
机构
[1] CHU Montpellier, Hop Gui De Chauliac, Pole Neurosci Tete & Cou, Dept ORL Chirurg Cerv Faciale, F-34295 Montpellier, France
[2] CHU Montpellier, CHRU Montpellier, Hop Lapeyronie, Dept Endocrinol, F-34295 Montpellier, France
[3] Ctr Reg Lutte Canc Val Aurelle, Nucl Med Serv, F-34298 Montpellier 5, France
关键词
Differentiated thyroid cancer; PET-CT; Thyroglobulin; Recurrence; Scintigraphy; FOLLOW-UP; PREOPERATIVE ULTRASONOGRAPHY; SURGICAL-MANAGEMENT; LOCAL RECURRENCE; NODE-METASTASIS; PAPILLARY; IMPACT; CANCER; PET/CT; SURGERY;
D O I
10.1016/j.anorl.2012.01.003
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Objectives: Recurrence is observed in 15-20% of patients under surveillance following treatment of differentiated thyroid cancer (DTC). However, due to cell dedifferentiation, the recurrence may be iodine-negative, thereby compromising detection. For this reason, new methods of exploration are indispensable to enable localization of such recurrences. The purpose of this work is to review the contribution of positron emission tomography-computed tomography (PET-CT) in the exploration of iodine-negative recurrent DTC. Method: A comprehensive review and discussion of the medical literature was carried out. Results: Depending on the report, the sensitivity of PET-CT ranged from 70% to 85%, with up to 90% specificity. However, the large number of false negatives, which can reach 40%, is the disadvantage of this examination. PET-CT results lead to change in the therapeutic strategy in approximately 50% of patients with isolated raised serum thyroglobulin levels, and surgical exploration of a precise anatomical area in the neck. Conclusion: As post-treatment recurrence of a DTC can affect patient survival, a thorough diagnostic work-up is required in these cases. Where thyroglobulin levels are elevated with no uptake on 131-iodine scans, PET-CT can be a useful complementary exploration, especially for localizing the site of recurrence. (C) 2012 Published by Elsevier Masson SAS.
引用
收藏
页码:251 / 256
页数:6
相关论文
共 38 条
[1]  
Baudin E, 1999, REV FR ENDOCRINOL CL, V40, P529
[2]  
Daou D, 2001, J NUCL MED, V42, p178P
[3]   Algorithm for safe and effective reoperative thyroid bed surgery for recurrent/persistent papillary thyroid carcinoma [J].
Farrag, Tarik Y. ;
Agrawal, Nishant ;
Sheth, Sheila ;
Bettegowda, Chetan ;
Ewertz, Marjorie ;
Kim, Matthew ;
Tufano, Ralph P. .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2007, 29 (12) :1069-1074
[4]   Dual-modality FDG-PET/CT in follow-up of patients with recurrent iodine-negative differentiated thyroid cancer [J].
Freudenberg, Lutz S. ;
Frilling, Andrea ;
Kuehl, Hilmar ;
Mueller, Stefan P. ;
Jentzen, Walter ;
Bockisch, Andreas ;
Antoch, Gerald .
EUROPEAN RADIOLOGY, 2007, 17 (12) :3139-3147
[5]   Preoperative diagnostic value [18F] fluorodeoxyglucose positron emission tomography in patients with radioiodine-negative recurrent well-differentiated thyroid carcinoma [J].
Frilling, A ;
Tecklenborg, K ;
Görges, R ;
Weber, F ;
Clausen, M ;
Broelsch, EC .
ANNALS OF SURGERY, 2001, 234 (06) :804-811
[6]   Is [18F]-2-fluoro-2-deoxy-D-glucose (FDG) scintigraphy with non-dedicated positron emission tomography useful in the diagnostic management of suspected metastatic thyroid carcinoma in patients with no detectable radioiodine uptake? [J].
Giammarile, F ;
Hafdi, Z ;
Bournaud, C ;
Janier, M ;
Houzard, C ;
Desuzinges, C ;
Itti, R ;
Sassolas, GV ;
Borson-Chazot, F .
EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2003, 149 (04) :293-300
[7]   The clinical impact of 18F-FDG gamma PET in patients with recurrent well differentiated thyroid carcinoma [J].
Goshen, E ;
Cohen, O ;
Rotenberg, G ;
Oksman, Y ;
Karasik, A ;
Zwas, ST .
NUCLEAR MEDICINE COMMUNICATIONS, 2003, 24 (09) :959-961
[8]  
GRANT CS, 1988, SURGERY, V104, P954
[9]   Thyroglobulin monitoring after treatment of well-differentiated thyroid cancer [J].
Hamy, A ;
Mirallié, E ;
Bennouna, J ;
Resche, I ;
Drefty, C ;
Johnstone, M ;
Visset, J .
EJSO, 2004, 30 (06) :681-685
[10]   Impact of primary surgery on outcome in 300 patients with pathologic tumor-node-metastasis stage III papillary thyroid carcinoma treated at one institution from 1940 through 1989 [J].
Hay, ID ;
Bergstralh, EJ ;
Grant, CS ;
McIver, B ;
Thompson, GB ;
van Heerden, JA ;
Goellner, JR .
SURGERY, 1999, 126 (06) :1173-1181